Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.63 |
| ▸ | CDK9 | P50750 | 1/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9725165 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL28348692 | 0.86 | NPC1 (0.55) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL10650999 | 0.86 | MEN1 (0.51) | SMN1; SMN2EPHX1TSHREPHX2KMT2A | |
| SCHEMBL16568339 | 0.86 | MAOA (0.64) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL6033544 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| Diphenylurea SCHEMBL133103 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| SCHEMBL3996276 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| Diphenylurea SCHEMBL3037927 | 0.77 | SMN1; SMN2 (0.94) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| Diphenylurea SCHEMBL28431956 | 0.77 | SMN1; SMN2 (0.94) | SMN1; SMN2TP53EPHX1TSHREPHX2 | |
| Diphenylurea SCHEMBL30786615 | 0.77 | SMN1; SMN2 (0.94) | SMN1; SMN2TP53EPHX1TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301464-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2003-04-16 | — | — | EP | claimed |
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-14 | — | — | US | claimed |
| WO-2002004403-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-01-17 | — | — | WO | claimed |
| EP-3523134-A1 | HEAT-SENSITIVE RECORDING MATERIAL | Mitsubishi HiTec Paper Europe GmbH (DE) | 2019-08-14 | — | — | EP | disclosed |
| EP-3352991-A1 | HEAT-SENSITIVE RECORDING MATERIAL | Mitsubishi HiTec Paper Europe GmbH (DE) | 2018-08-01 | — | — | EP | disclosed |
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| US-7329681-B2 | Inhibitors of IMPDH enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-12 | — | — | US | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
| US-20050282876-A1 | Ligands for Inosine-5'-monophosphate dehydrogenase; antiviral, antiinflammatory, antibiotics, transplant rejection, autoimmune disease, , antipsoriatic immunosuppressants; 3-uriedo benzyl carbamate derivatives; high potency, side effects reduction; bioavailability; antivascular hyperproliferative | VERTEX PHARMACEUTICALS INCORPORATED | 2005-12-22 | — | — | US | disclosed |
| US-6967214-B2 | Inhibitors of IMPDH enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-22 | — | — | US | disclosed |
| EP-1301464-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2003-04-16 | — | — | EP | disclosed |
| US-6541496-B1 | Inosine-5'-monophosphate dehydrogenase inhibitors; merimepodib; hepatitis | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-01 | — | — | US | disclosed |
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-14 | — | — | US | disclosed |
| US-6344465-B1 | INOSINE MONOPHOSPHATE DEHYDROGENASE; merimepodib; transplant rejection, autoimmune diseases, multiple sclerosis, juvenile diabetes, asthma, inflammatory diseases, lymphoma or leukemia, and hyperproliferative vascular diseases | VERTEX PHARMACEUTICALS, INCORPORATED | 2002-02-05 | — | — | US | disclosed |
| WO-2002004403-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | MTTP, CETP, FABP1 | SMN1; SMN2 4752/4885TP53 4688/4885EPHX1 1716/4885 |
| US-20050282876-A1 | Ligands for Inosine-5'-monophosphate dehydrogenase; antiviral, antiinflammatory, antibiotics, transplant rejection, autoimmune disease, , antipsoriatic immunosuppressants; 3-uriedo benzyl carbamate derivatives; high potency, side effects reduction; bioavailability; antivascular hyperproliferative | IMPDH1, IMPDH2, UMPS | SMN1; SMN2 4822/4885TP53 3267/4885EPHX1 2114/4885 |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | SMN1; SMN2 1864/4885TP53 895/4885EPHX1 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.